Company profile
Braxia Scientific Corp.
OTC: BRAXF · Healthcare · Biotechnology
Canadian filerHQ Mississauga, ONReports USD
#837 of 1,418 Healthcare companies by revenue66th-percentile growth
EA Score
——FH —DQ —GM —SS 21
v0.1 · 5/100 weight · pillars only
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ growth stability, return on equity
Methodology →Revenue TTM
$1.6M
Rev growth YoY (TTM)
+23.3%
Net income (FY)
-$9.9M
Employees
5
as of 2026-08-29
Market cap
$28.3k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.4M1.9M CAD2023
Net income-$9.9M-13.1M CAD2023
Operating income-$5.7M-7.5M CAD2023
Total assets$2.9M3.9M CAD2023
Liabilities$1.7M2.3M CAD2023
Equity$1.2M1.6M CAD2023
Revenue trend
FY2020 – FY2023 · USD
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Braxia Scientific Corp.’s revenue?
Braxia Scientific Corp. booked $1.4M in FY2023 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a -697.5% net margin.
Peers · Healthcare
American Green, Inc.51DDaxor Corporation——Perspective Therapeutics, Inc.46DOutlook Therapeutics, Inc.22DAvenue Therapeutics, Inc.25DWinston Pharmaceuticals, Inc.——Key facts
CEOPeter Rizakos
SectorHealthcare
IndustryBiotechnology
HeadquartersMississauga, ON
ExchangeOTC: BRAXF
Employees5
IPO date2020-03-25
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.